Lilly is the latest pharma company to use M&A to enter this growing field, following deals made in the past year by ...

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

Chimeric antigen receptor (CAR) T cell therapy, a type of immunotherapy that leverages the immune system to combat diseases, ...

New therapy reprograms immune cells inside tumors to attack cancer, bypassing traditional cell therapy manufacturing ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.

A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...